Scarica l'app Stockscreener
25.11
0.56%
0.14
Dopo l'orario di chiusura:
25.11
Precedente Chiudi:
$24.97
Aprire:
$24.94
Volume 24 ore:
527.34K
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.51B
Reddito:
$13.05M
Utile/perdita netta:
$-60.54M
Rapporto P/E:
-21.65
EPS:
-1.16
Flusso di cassa netto:
$-37.82M
1 W Prestazione:
+9.99%
1M Prestazione:
-2.52%
6M Prestazione:
-30.96%
1 anno Prestazione:
-39.52%
Intervallo 1D:
$24.53
$25.14
Intervallo di 1 settimana:
$21.97
$25.93
Portata 52W:
$21.97
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
25.11 | 1.50B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
What makes Janux Therapeutics Inc. stock price move sharplyWeekly Risk Report & Smart Investment Allocation Insights - sundaytimes.kr
Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations - TipRanks
Janux Therapeutics Inc. At Critical Juncture — Bounce or BreakdownJuly 2025 Retail & Fast Moving Stock Trade Plans - sundaytimes.kr
Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials - TipRanks
Janux Therapeutics Inc. Sees Relief Buying After Extended Drop2025 Institutional Moves & Fast Moving Stock Trade Plans - metal.it
What are JACS’s earnings expectationsConsistent Triple Digit Profits - classian.co.kr
EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, - openPR.com
EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux - Barchart.com
Promising Pipeline and Financial Stability Support Buy Rating for Janux Therapeutics Inc - TipRanks
Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target - TipRanks
Janux Therapeutics Earns Buy Rating Amid Promising Pipeline and Strong Financial Position. - AInvest
RSI Crosses Above 30 for Janux Therapeutics Inc. — Reversal in SightTarget Return Focused Trade Insights Shared - metal.it
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position - TipRanks
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $59 to $100 - 富途牛牛
Janux Therapeutics 2024 Q3 Earnings Widening Losses Amidst Revenue Decline - AInvest
Janux Therapeutics stock hits 52-week low at 22.25 USD - Investing.com
Janux Therapeutics stock hits 52-week low at 22.25 USD By Investing.com - Investing.com Nigeria
Janux (JANX) R&D Soars Revenue Misses - AOL.com
Janux Therapeutics Reports Q2 2025 Financial Results - TipRanks
Janux Therapeutics 2024 Q3 Earnings Deepening Losses Amid Pipeline Progress - AInvest
Janux Therapeutics Stock Maintains Buy Rating: Strong Cash Position and Promising '007 Program Drive Optimism - AInvest
Optimistic Outlook for Janux Therapeutics: Strong Cash Position and Promising ‘007 Program Drive Buy Rating - TipRanks
Optimistic Buy Rating for Janux Therapeutics Inc. Driven by Promising R&D, Strong Cash Position, and Strategic Expansion - TipRanks
Janux Therapeutics reports Q2 EPS (55c), consensus (47c) - TipRanks
Janux Therapeutics Reports Q2 FY25 Financial Results, $996mln Cash, Milestone Payment from Merck. - AInvest
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics shares fall 4.94% intraday despite dosing first patient in TRACTr collaboration with Merck. - AInvest
Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration - TipRanks
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
Is Janux Therapeutics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
What analysts say about Janux Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What are the latest earnings results for Janux Therapeutics Inc.Build wealth faster with consistent investment plans - Jammu Links News
Should I hold or sell Janux Therapeutics Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What drives Janux Therapeutics Inc. stock priceExplosive trading growth - Jammu Links News
Janux Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with expert advice - Jammu Links News
How does Janux Therapeutics Inc. generate profit in a changing economyMaximize your gains with professional insights - Jammu Links News
Is Janux Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsUnlock your portfolio’s hidden potential - Jammu Links News
How does Janux Therapeutics Inc. compare to its industry peersAccelerated financial growth - Jammu Links News
Can Janux Therapeutics Inc. Regain Momentum After BreakdownReal Trader Watchlist of Hot Stocks Released - metal.it
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
Janux Therapeutics Receives Buy Rating from Leerink Partners Analyst Jeffrey La Rosa - AInvest
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Praise Ionis Pharmaceuticals and Janux Therapeutics for Bright Healthcare Futures - AInvest
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):